• Endonovo Therapeutics is developing bioelectronic devices that target patient pain, inflammation and wound recovery
• The company intends to get its flagship SofPulse device into 600 hospitals within the next 18 months as part of its bid to reduce post-operative drug dependence
• Drug dependence is regarded as a major contributor to a global opioid epidemic that has driven advocacy for less harmful pain drugs, increased governmental funding and new sentencing protocols for drug-related crimes
• The U.S. government has spent $2.4 billion during the past two years on addiction intervention amid statistics showing pain-killer death totals in the tens of thousands each year

Worldwide concerns about pain relief medication-induced addictions and deaths have led to a variety of societal changes during recent years, most notably driving the multinational advocacy for medical marijuana (cannabis) as a potential palliative without the degree of harmful effects from prescription and illegal narcotics, while also spawning increasing calls for governmental funding to fight addiction and change the judicial system’s approach to drug-related crimes. Amid some concerns about how private industry and governmental agencies are responding to the opioid epidemic/pandemic, Endonovo Therapeutics Inc. (OTCQB: ENDV) is advancing novel bioelectronic device solutions that are non-invasive and sidestep the drug issues entirely.

Endonovo Therapeutics is a commercial-stage developer of medical implements designed to provide proprietary, patent-protected electroceutical therapy for treating patient pain, inflammatory conditions, cardiovascular diseases and central nervous system disorders. The company’s flagship product, SofPulse, uses targeted electrical microcurrents to gently help reduce tissue swelling and speed up the natural recovery process.

Endonovo’s electroceutical therapy has received clearance for the palliative treatment of post-surgical pain and edema (swelling) from the U.S. Federal Drug Administration, has national coverage from the Centers for Medicare and Medicaid Services in chronic wound treatment and maintains a CE-mark certification that indicates conformity with European Economic Area health and environmental protection standards related to wound, pain and edema treatment.

On June 13, the company detailed its initial strategy for a national rollout of its SofPulse targeted pulsed electromagnetic field (tPEMF) therapy device to hospitals throughout the United States. According to the company’s news release, Endonovo plans to be in the evaluation stage with 600 hospitals within the next 18 months, employing 300 sales representatives (http://ibn.fm/gAHv2).

“After careful consideration and discussions, and in accordance with our internal budgets, we have reached the point at which we can confidently announce our national rollout plan and strategy,” CEO Alan Collier stated in a new release. “We believe, based on numerous meetings with doctors and hospital administrators, the level of acceptance of our SofPulse device supports our plans to be in hospitals throughout all 50 states by 2020. With the public demanding change and options other than opioids, and with very few alternatives to satisfy those demands, SofPulse is a natural and safe replacement to opioids and a solution to this health crisis.”

The federal government has provided at least $2.4 billion in grant money since 2017 to reduce opioid addiction, citing statistics reporting tens of thousands of drug addiction-related deaths each year, although reform advocates complain that the medical marijuana-fueled policy changes are too narrow in scope (http://ibn.fm/E67V1). Additional proposed legislation would provide a more widespread continuum of care for drug recovery, but at a cost of billions of dollars in taxpayer payouts (http://ibn.fm/5QOPp).

At the same time, media reports on new research are countering prior claims that states with legal medicinal marijuana had seen fewer opioid overdose deaths than states without legal medical cannabis, showing that addiction-related deaths in medical cannabis-legal states have actually been increasing (http://ibn.fm/X8gzJ) and indicating that “cannabinoids have demonstrated therapeutic benefits, but reducing population-level opioid overdose mortality does not appear to be among them,” according to a piece published by The Philadelphia Inquirer (http://ibn.fm/MPi3t).

Endonovo’s SofPulse device aims to elevate discussion of non-drug solutions to the addiction crisis (http://ibn.fm/tXlin), noting that, as the device reduces edema and pain levels, thereby decreasing the requirement for medication, “patients can move around sooner, which stimulates the body’s natural response to healing… (And) unlike prescription medications, SofPulse has no known side effects.” The company has filed an 8-K with the Securities and Exchange Commission, providing its new nationwide marketing plan with sales projections.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• The rising global popularity of cannabidiol as a wellness product is leading market forecasts of revenues up to $22 billion by 2022 and $50 billion or more by the end of the next decade
• The market optimism is fueling hopes for ancillary market players as well, such as hydroponics equipment supplier Sugarmade Inc.
• Sugarmade announced this month that it will enter the hemp CBD extraction equipment market, drawing on access to advanced Chinese extraction technologies

The health and wellness market sector for cannabidiol (CBD) products continues to grow at such a pace that analysts at the Brightfield Group predict that revenues could reach $22 billion per year by 2022 and, per various Wall Street estimates, approach $50 billion or even $75 billion by 2029-30, as noted in a media report carried by Nasdaq (http://ibn.fm/5Wlme).

The potency of CBD’s sales estimates are encouraging to Sugarmade Inc. (OTCQB: SGMD), which announced this month that it is expanding on its hydroponics supply model for the agriculture industry to enter the hemp extraction equipment and technologies market (http://ibn.fm/RIIAy). In addition to supplying “legacy extraction equipment to extraction companies,” Sugarmade plans to begin distribution of “next generation extraction technologies developed in the Chinese province of Yunnan where the hemp industry has existed for more than a thousand years,” CEO Jimmy Chan stated in a news release.

The proprietary Chinese technologies hold the promise of increasing the efficiency of production processes used in hemp cultivation and extraction – the primary source of CBD – at a time when hemp cultivation is enjoying a resurgent popularity in the United States in tandem with federal legalization under last year’s Farm Bill (http://ibn.fm/W0vuh).

“It is clear the 2019 and 2020 hemp cultivation seasons will be massive,” Chan added. “Our staff has done extensive research into the fast-growing hemp industry. We continue to see an imbalance between cultivation outputs and extraction capacities within the industry. This leads us to believe the market for extraction services and the equipment required by these extraction companies will continue to accelerate.”

The company cites U.S. Department of Agriculture forecasts anticipating that farm production will generally decrease nationwide, while hemp production is expected to defy the trend as states such as Kentucky, Colorado, Oregon and North Dakota report sizable increases in hemp acreage and applications to begin cultivating hemp. In April, Kentucky’s state agriculture commissioner told a CNBC news reporter that he expects the number of hemp acres in Kentucky to increase from 16,000 to 50,000 this year, with a corresponding increase in applications for hemp cultivation (http://ibn.fm/e0Qsq).

Sugarmade has been building on an agreement with Kentucky-based hemp cultivator Hempistry Inc. to deliver resources for plant micropropagation work. Micropropagation involves cloning or “propagating” new hemp plants from existing “mother” plants that demonstrate superior qualities. A lot of North America’s hemp is grown using propagation techniques instead of by planting new seeds, which may carry greater risks of poor productivity. The propagation technique also allows the company to harvest a large number of plants simultaneously.

For more information, visit the company’s website at www.Sugarmade.com

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SUGAR

• The Green Organic Dutchman is a premium, international organic cannabis company
• TGOD recently secured a cannabis supply agreement with Alberta Gaming, Liquor and Cannabis
• The company has a partnership with the world’s second-largest power-management company

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) grows high-quality, organic cannabis with sustainable, all-natural principles. A premium global organic cannabis company headquartered in Mississauga, Ontario, TGOD focuses on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD’s products are laboratory tested to ensure that patients have access to a standardized, safe, consistent product. The company’s organic process involves transparent, sustainable steps and principles to produce certifiable quality.

TGOD has a planned capacity of 219,000 kg and is constructing 1.64 million square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. Additionally, TGOD has organic hemp, CBD oil operations in Canada. Furthermore, through wholly owned subsidiary HemPoland, the company distributes premium hemp CBD oil in the European Union. TGOD’s Ancaster, Ontario, operations span 166,000 square feet of high-tech facilities capable of producing 17,500 kg of high-quality organic cannabis annually (http://ibn.fm/qATad).

Recently, TGOD announced its entry into a cannabis supply agreement with Alberta Gaming, Liquor and Cannabis (AGLC). This further expands TGOD’s presence in Western Canada. AGLC, under the brand Alberta Cannabis, is Alberta’s legal, nonmedical, online cannabis store (http://ibn.fm/LJyIf).

The agreement with AGLC was negotiated in association with Velvet Management Inc. Velvet Management provides a fully integrated, national sales and distribution platform for TGOD’s premium organic cannabis to provincial liquor and cannabis boards.

“Alberta is an important market for us as we continue to expand our distribution channels across Canada,” TGOD CEO Brian Athaide said in a news release. “With our production facilities in Hamilton, Ontario, and Valleyfield, Quebec, coming online in phases, we are thrilled to start distributing TGOD’s premium certified-organic cannabis to AGLC.”

TGOD also recently reported the distribution of unit purchase warrants (“SpinCo Unit Warrants”) of TGOD Acquisition Corp. (“SpinCo”) to all registered TGOD shareholders of record as of January 31, 2019, who elected to receive the SpinCo Unit Warrants under the company’s earlier announced plan of arrangement with SpinCo (http://ibn.fm/EUgib). SpinCo is an investment company guided by an investment policy that’s mainly focused on investments in the cannabis industry in Canada and worldwide.

TGOD has a partnership with Eaton, the world’s second-largest power-management company. Eaton promises to supply innovative and cost-effective power solutions to meet TGOD’s increasing demands. In addition, construction management is supplied by Ledcor, Canada’s second-largest multidisciplinary construction company. Ledcor is a pioneer in the green building industry.

The future for TGOD includes its strategic beverage division. The expectation is that this will be an organic research and development (R&D) center, which will focus on novel and proprietary cannabinoid-infused beverages, advanced product development and pilot manufacturing for novel and proprietary cannabinoid-infused beverages, advanced product development and pilot manufacturing (http://ibn.fm/1XOwi).

TGOD continues to focus on first-class products that demand a premium in the market. With its strategic partnerships, global growth and world-class executive team, the company offers investors the potential for healthy ROI. By growing organically and operating at low costs, TGOD is well positioned to become the worldwide leader in delivering premium organic-cannabis solutions designed to enhance lives.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

• Willow has entered a joint development agreement with Noramco Inc. that includes a plan to develop a yeast-based biosynthesis platform to produce low-cost CBD for the pharmaceutical, food, beverage and personal care markets
• The agreement has the potential to open the door to new and larger markets for CBD and related compounds
• Terms of the agreement call for the parties to cover their own costs, retain their own intellectual property (IP) and share equally in gross profits

Willow Biosciences Inc. (CSE: WLLW) has entered a joint development agreement (“JDA”) with Noramco Inc. to develop a biosynthesis platform for the production of CBD (http://ibn.fm/2ig1X). The result could be far-reaching, developing low-cost, ultra-pure CBD products for pharmaceutical, food, beverage and personal care consumers. The work has the potential to provide access to new and larger markets for CBD and related compounds.

The JDA requires each company to cover its own costs, retain its own intellectual property associated with its own scopes of work and share equally in the gross profits from sales of CBD produced under the agreement.

Based in Calgary, Canada, Willow Biosciences produces high-value, plant-derived biosynthetic compounds. In the cannabinoid field, the company owns proprietary, yeast-based lab strains that produce CBD, THC and cannabigerol (CBG), as well as other minor and novel cannabinoids. Noramco, based in Wilmington, Delaware, is the world’s largest producer of high-quality synthetic cannabinoid active pharmaceutical ingredients (API) for the pharmaceutical and health care industry.

The JDA calls for WLLW to be responsible for optimizing yeast strains in a biosynthetic process that is expected to generate ultra-pure CBD at a lower cost and higher yield than current methods. Noramco will be responsible for scale up, regulatory submission, marketing and distribution.

“They are the obvious first choice as a partner to scale the development of our CBD biosynthesis program,” WLLW Executive Chair Dr. Joseph Tucker stated in a news release (http://ibn.fm/LjPRC). “Noramco’s global leadership program in the production and sales of cannabinoids to pharmaceutical companies will naturally lead into manufacturing and sales into additional nonpharmaceutical markets.”

Bill Grubb, Noramco’s chief innovation officer and VP of global business development, said in a news release (http://ibn.fm/Eh68Y) that the agreement would give Noramco “the capacity to address rapidly increasing market demand for CBD-based APIs and ingredients from pharmaceutical, nutraceutical, consumer packaged goods, beverage and other industry sectors.”

For more information, visit the company’s website at www.WillowBio.com

• Plus Products has the right – but no obligation – to buy Emerald Bay Wellness and the business assets of Emerald Bay Extracts
• Emerald Bay Extracts has been one of Plus Products’ largest suppliers for the past year
• If the option is exercised, PLUS will reap the benefits of vertical integration and directly interact with the cannabis plant

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF), manufacturer and marketer of cannabis food products, has purchased an option to buy California-based cannabis oil manufacturer Emerald Bay Wellness LLC and the business assets of Emerald Bay Extracts. The option specifies cash and stock consideration for PLUS to acquire one of its largest cannabis oil suppliers and a supply partner for more than a year (http://ibn.fm/8rbu3).

In consideration for the option, PLUS intends to deliver a $400,000 secured loan to Emerald Bay Extracts. If the acquisition option is exercised, terms call for the issuance of approximately 1.2 million subordinate voting shares of PLUS and $250,000 in cash; in addition, Emerald Bay would not be required to repay the original loan. Some 70 percent of the deal’s consideration would be subject to performance revenue, which totals almost $28 million over a two-year, earn-out period (http://ibn.fm/H4B7a).

“We targeted this acquisition because it allows us to reap the benefits of vertical integration while maintaining a focus on product manufacturing,” PLUS CEO Jake Heimark stated in a news release (http://ibn.fm/ETibU). “Ultimately, this is a rare opportunity to improve quality control, cut costs and grow revenues all at the same time.” Heimark added that acquiring Emerald Bay would give PLUS the opportunity to “directly interact with the cannabis plant.”

If exercised, the option would give Plus Products in-house cannabis extraction capabilities that could improve quality control and raise gross margins on its core edibles business. Exercising the option could also create a new revenue stream and product development capabilities.

San Mateo, California-based PLUS is a cannabis-infused branded products manufacturer selling to regulated medicinal and adult-use recreational markets in California and Nevada. PLUS is focused on building the largest cannabis brand by growing organically and through acquisitions.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF

• An aging Western population and the prevalence of chronic diseases are expected to contribute to the massive growth of the wearable medical devices market in the years to come
• Companies like Endonovo Therapeutics are primed to benefit from the growth opportunities due to innovative developments that are currently in the clinical stages
• Endonovo’s wearable medical device can be used to address an array of medical conditions; it promotes faster post-surgery and wound healing and can also effectively manage inflammatory processes in the body

The global wearable medical devices market is anticipated to grow to $66.8 billion by 2026, a Grandview Research report published in April 2019 suggests (http://ibn.fm/AzXnV). The market is forecast to expand at a CAGR of 26.1 percent over the period, with several factors contributing to the growth.

Increased health awareness and a better understanding of the need for constant monitoring will both help the market expand. In addition, the Western world’s population is aging, and the prevalence of chronic medical conditions is increasing. Wearable devices can be used to monitor various important health parameters, to prompt a more active lifestyle and even to address an array of treatable conditions.

In response, three main types of medical devices are expected to emerge and dominate the market – pain management, respiratory therapy and glucose monitoring devices, according to Allied Market Research (http://ibn.fm/VvEOV).

Based on these forecasts, companies like Endonovo Therapeutics Inc. (OTCQB: ENDV) are anticipated to leverage new opportunities to strengthen their market positions. Endonovo Therapeutics develops, manufactures and distributes wearable medical devices for pain management and the control of inflammatory processes. The wearable medical devices are non-invasive and designed to deliver the company’s proprietary Electroceutical therapy, which targets cardiovascular diseases, central nervous system disorders, kidney diseases and inflammatory conditions.

The SofPulse device by Endonovo is designed to deliver pulsed electromagnetic frequencies – a therapeutic approach that’s especially beneficial for the promotion of recovery in the aftermath of surgical procedures.

Endonovo’s wearable medical device can be used as a standalone therapy or as a part of a treatment protocol. The pulsed electromagnetic therapy aids in the reduction of swelling, and it also speeds up natural recovery processes. Since SofPulse reduces the pain and inflammation related to recovery from surgeries or trauma, the need for using prescription medications and other pain control options is diminished.

Studies carried out to date to test the effectiveness of the wearable medical device demonstrate its ability to reduce narcotics use in the first 48 hours after surgery by 2.2 times. Patients who are not in great pain and who don’t need to take prescription pain management pharmaceuticals could start moving around sooner, which has been shown to promote faster recovery through natural healing processes.

Endonovo received U.S. FDA clearance for the palliative treatment of pain and post-surgical swelling with SofPulse. In Europe, the medical device is CE-marked for the promotion of wound healing and the palliative treatment of pain and post-surgical swelling.

Endonovo’s current portfolio of wearable medical products addresses conditions like liver disease, chronic kidney disease, cardiovascular and peripheral artery disease and ischemic stroke.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• Sharing Services Global Corporation has inspired a league of passionate Elepreneurs who are taking charge of their own success
• Analysts suggest that the direct sales market is on the brink of a “transformational moment”
• The direct sales market continues to increase in value and evolve in strategy

Sharing Services Global Corporation (OTCQB: SHRG), a diversified holding company that owns, operates or controls an interest in a variety of companies specializing in the direct selling industry, continues to weather the storms of shifting market trends by combining enthusiastic independent sales representatives with its creative brand strategy.

The company has been riding a wave of success by implementing its Blue Ocean Strategy, described as creating a paradigm shift in a formerly stagnant industry. By shifting the company’s focus from merely selling a product to empowering individuals, Sharing Services has inspired a league of passionate Elepreneurs who are taking charge of their own success.

Elepreneurs, one of the company’s wholly owned subsidiaries, synthesizes several vital strands, including elevating home-based entrepreneurs, generating 100 percent organic growth through direct selling and creating successful independent business leaders who add value to the Sharing Services business model and benefit from its mentorship and support (http://ibn.fm/HFUMl).

By investing in people as the lifeblood of its company, Sharing Services has been able to market Elepreneurs in ways that meet the new era of social media. The company’s mission is to empower its people to achieve healthy minds and bodies, happiness in quality of life and wealth accumulation (http://ibn.fm/mQ7c8). Word-of-mouth, or relationship marketing, is organically activated through these company representatives. The end result is increased revenues for Sharing Services and value for its shareholders, as well as an intrinsically loyal and ever-growing team of Elepreneurs who see the value of the company’s products and philosophy.

As a burgeoning market, the direct sales industry has seen tremendous growth in recent years. A record 20.5 million people were involved in direct selling in the United States during 2016, signifying a 1.5 percent increase from the previous year. Similarly, the estimated direct retail sales of $35.54 billion in 2016 was the second highest in direct selling history, and these numbers continue to grow.

The future of direct sales looks bright and is on the brink of a transformational moment, according to the Direct Selling Association. “It seems clear… that our business model is poised to make the next big jump into the future,” Joseph Mariano wrote on behalf of the association. With much of the consumer population shifting to online shopping, direct sellers must stay abreast of industry changes and consider how technology is changing the face of direct selling. “What our industry does during the coming months will shape our future,” Mariano noted (http://ibn.fm/8GST2), indicating that direct-selling industry numbers “are a strong indicator of where direct selling is and where we are going, and that clearly is the ‘way forward’.”

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Two executives from SHRG subsidiary Elepreneur have been named as new SHRG board members
• Four independent outside members will join the board as the company continues to pursue uplisting to the Nasdaq
• Company CFO Frank Walters has resigned from the board; he will continue as CFO with a focus on the uplisting process

Sharing Services Global Corporation (OTCQB: SHRG) has named Elepreneur President Keith Halls and Elepreneur CEO Kip Allison as members of the SHRG board. Additionally, SHRG plans to add four independent members to its board as it pursues an uplisting to the Nasdaq, according to SHRG CEO John “JT” Thatch.

“We are finalizing our year-end audit and undertaking preliminary steps to expand our board of directors with four qualified, independent outside members,” Thatch stated in a news release (http://ibn.fm/ceiPl). “A search committee has been commissioned to begin this process as we continue the Nasdaq uplist process.”

SHRG CFO Frank Walters has resigned as a board member but will continue as CFO and will concentrate on the uplisting process and the continued growth of the company.

Halls has been with SHRG since August 2018. He brings a long history of success, both on the distributor and corporate sides. He began in the direct-selling industry in 1986 when he joined NuSkin Enterprises, eventually serving as senior vice president and a board member in that organization. He left NuSkin in 2001, becoming a distributor and part of the sales force for numerous companies.

Allison was originally retained by the company last year as outside counsel and to assist in the operational structure. Prior to that, he was with DF&R Inc. for 10 years in corporate operations. He earned a law degree from the SMU School of Law and built a legal practice focused on closely held corporations. He was the principal and managing partner of his litigation firm until he joined Elepreneur as CEO.

SHRG is a Plano, Texas-based diversified holdings company that owns, operates or controls a variety of companies engaged in direct selling through independent sales representatives. The company also offers services in the energy, technology and insurance sectors. Its divisions include Elevacity Global LLC and Elepreneur LLC.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Siyata Mobile is offering a new category of cellular device designed to make commercial vehicle technology safer and more efficient for drivers on the road
• The company recently announced that its Uniden UV350 in-vehicle mounted phablet is now FirstNet Ready, making it tested and approved for use on the FirstNet communications platform
• With approval for use on both the AT&T and FirstNet Networks, the company is now open to a large untapped U.S. marketplace of first responders and commercial vehicles

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) has now launched its FirstNet Ready Uniden UV350 4G/LTE In-Vehicle Device for Public Safety (http://ibn.fm/pcM9P), representing a milestone in the company’s development. Siyata’s UV350 is the first in-vehicle mounted phablet that’s been tested and approved for use on both the AT&T and FirstNet networks.

“We have been working for the past two years to launch at U.S. carriers,” CEO and Board Chairman Marc Seelenfreund said in an interview with InvestorIntel published last month (http://ibn.fm/2Tw1N). “This is a very long process and very few companies are able to actually achieve device approvals at the U.S. carriers. Now that we have launched with AT&T and FirstNet, we can begin targeting a very large-scale opportunity in the United States.”

Siyata’s flagship products are designed to establish a new category of cellular communication devices dedicated to commercial vehicle use. The UV350 is a 4G/LTE device that utilizes Push-to-Talk Over Cellular (PoC) technology to promote a safe way for commercial vehicle drivers to communicate on the road – eliminating potential distractions that might occur when multiple devices come into play for managing vehicle functions and transmissions.

“Our research suggests, there are approximately 10 million commercial vehicles in the United States and over 3 million first responder vehicles in the United States. So, we’re going after a market, just in North America, of over 13 million commercial vehicles and we’re the only ones, with a dedicated in-vehicle device like this to target this market opportunity,” Seelenfreund added.

For more information, visit the company’s website at www.SiyataMobile.com

NOTE TO INVESTORS: The latest news and updates relating to SYATF are available in the company’s newsroom at http://ibn.fm/SYATF

• The company has a seasoned management team with more than 50 years of experience
• VPR Brands is focused on sustainable, manageable growth and continued product excellence
• The company is a relatively unknown, award-winning cannabis firm

VPR Brands LP (OTC: VPRB) is a technology holding company located in Fort Lauderdale, Florida, specializing in vaporizers and accessories for essential oils, cannabis concentrates and extracts and electronic cigarettes. The company holds U.S. and Chinese patents for atomization-related products. VPR Brands’ broad portfolio of tested vaporizer products is driving sales and supporting strong year-over-year financial growth.

The strength of the company lies in its management team. Together, team members have more than 50 years of experience in distribution and product development within the vaporizer industry. CEO Kevin Frija’s 29 years of experience reach into sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. His achievements include growing Vapor Corp. into one of the largest and most recognized companies in its space during his time as president and CEO.

COO Dan Hoff also spent time at Vapor Corp., expanding its distribution network and overseeing financial management, accounting functions, supply chain management, product design and development, and key vendor relations. Hoff joined the VPR Brands team with the 2016 acquisition of Vapor Corp.’s medical cannabis vapes program and its related inventory.

VPRB is focused on sustainable, manageable growth centered on high-performance, high-quality products. With a product portfolio heavily weighted toward cannabis vapes and CBD products, the company is seeing a solid start to 2019. Q1 2019 financial results reported a revenue increase of approximately $1.3 million, while the company’s net loss decreased by approximately $11,000 (http://ibn.fm/7wziC).

Consumer taste and expectations drive the product design and formulation of VPR brands. By offering private labels, co-branded collaborations and white-label extractors, VPR has provided several award-winning vaporizers to top companies in the cannabis and CBD oil industries. This has added additional value to VPR’s personal product portfolio, which includes GoldLine, HoneyStick, Helium, Vaporin, Vaporx, GoldLine Hemp and Vapor Store Direct.

Having an in-house product development team allows the company to expand margins as it continues to develop additional products. Its current offerings include vaporizers, e-liquids, cannabis consumables, disposable vapes, batteries and tanks.

VPR Brands is an award-winning company in the cannabis sector that is not yet well known but is gaining the attention of the investment community. Its experienced management team, high-quality products, diversified brands and organic customer base have provided the company with continued growth since its beginnings.

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB